214273-17-3 Usage
General Description
"(2R)-4-(PhenylMethyl)-2-MorpholineMethanamine is a complex organic compound that is chemically structured using a combination of elements like carbon, hydrogen and nitrogen. Its molecular formula is C14H20N2O. Its chemical structure includes a morpholine ring, which is a six-membered ring composed of four carbon atoms, one oxygen atom and one nitrogen atom. This ring is further substituted with additional chemical entities such as a phenylmethyl group positioned at the fourth carbon of the morpholine ring alongside a methanamine group originating from the second carbon atom. The (2R) connotation before its name specifies the spatial arrangement of atoms within the chemical, representing its stereochemistry – the study of the three-dimensional structure of molecules. (2R)-4-(PhenylMethyl)-2-MorpholineMethanaMine potentially finds its usage in medicinal chemistry or as an intermediate in chemical synthesis. However, explicit details about its properties, reactivities or specific applications are not extensively documented in available resources."
Check Digit Verification of cas no
The CAS Registry Mumber 214273-17-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,4,2,7 and 3 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 214273-17:
(8*2)+(7*1)+(6*4)+(5*2)+(4*7)+(3*3)+(2*1)+(1*7)=103
103 % 10 = 3
So 214273-17-3 is a valid CAS Registry Number.
214273-17-3Relevant articles and documents
DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF
-
Page/Page column 48-49, (2012/07/28)
Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.
